myelodysplastic syndromes (MDS) | Page 16 | Aplastic Anemia and MDS International Foundation

myelodysplastic syndromes (MDS)

The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications

Author(s): 
Zhang L, McGraw KL, Sallman DA, List AF
Primary Author: 
Zhang L
Journal Title: 
Leuk Lymphoma
Original Publication Date: 
Dec 2016

TP53 gene mutations occurring in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are associated with high-risk karyotypes including 17p abnormalities, monosomal and complex

Bone Marrow Diseases: 

Relevance of prognostic factors in the decision-making of stem cell transplantation in Myelodysplastic Syndromes

Author(s): 
Duarte FB, Santos TE, Barbosa MC, Kaufman J, Vasconcelos JP, Lemes RP, Rocha FD, Coutinho DF, Zalcberg I, Vasconcelos PR
Primary Author: 
Duarte FB
Journal Title: 
Rev Assoc Med Bras
Original Publication Date: 
Oct 2016

The hematopoietic stem cell transplantation (HSCT) is the only curative alternative for Myelodysplastic Syndrome (MDS), but many patients are not eligible for this treatment, as there are several limiting factors, especially in the case of patients with low-risk MDS. The aim of this study is to discuss the factors that can guide the decision-making on referring or not a patient to HSCT. Three cases of MDS, two of which were submitted to HSCT are presented.

Bone Marrow Diseases: 

Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes.

Author(s): 
Komrokji RS
Primary Author: 
Komrokji RS
Journal Title: 
Am Soc Clin Oncol Educ Book
Original Publication Date: 
Jan 2017

Hypomethylating agents (HMAs) are the mainstay treatment of patients with

Bone Marrow Diseases: 

Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study

Author(s): 
Wang R, Zeidan AM, Yu JB, Soulos PR, Davidoff AJ, Gore SD, Huntington SF, Gross CP, Ma X
Primary Author: 
Wang R
Journal Title: 
Prostate
Original Publication Date: 
Nov 2016

BACKGROUND:

Bone Marrow Diseases: 

Erythropoietin administration is associated with improved T-cell properties in patients with myelodysplastic syndromes

Author(s): 
Deshet-Unger N, Oster HS, Prutchi-Sagiv S, Maaravi N, Golishevski N, Neumann D, Mittelman M
Primary Author: 
Deshet-Unger N
Journal Title: 
Leuk Res
Original Publication Date: 
Nov 2016

The immune system is impaired in

Bone Marrow Diseases: 

WT1 Expression in Patients with Myelodysplastic Syndromes: A Variety of Possibilities in Future Clinical Practice

Author(s): 
Ogata K
Primary Author: 
Ogata K
Journal Title: 
Acta Haematol
Original Publication Date: 
Nov 2016

mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-bidi-font-family:
"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA">No abstract available.

Bone Marrow Diseases: 

Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease

Author(s): 
Cerchione C, Cerciello G, Avilia S, Pepa RD, Pugliese N, Picardi M, Catalano L, Pane F
Primary Author: 
Cerchione C
Journal Title: 
Blood Transfus
Original Publication Date: 
Oct 2016

mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-bidi-font-family:
"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA">No abstract available.

Bone Marrow Diseases: